- Poster presentation
- Open Access
Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment
BMC Proceedings volume 7, Article number: P19 (2013)
Head and neck cancer (HNC) is the 8th most common malignancy worldwide. Despite advances in therapeutic options over the last few decades, treatment toxicities and overall clinical outcomes have remained disappointing, underscoring a need to develop novel therapeutic approaches, particularly those that enhance tumor cell death, while minimizing damage to the surrounding normal tissues.
Materials and methods
An RNA interference (RNAi)-based high-throughput screen (HTS) was performed for the large-scale identification of novel genes that will selectively sensitize HNC cells to ionizing radiation. The Dharmacon Protein Kinase and Druggable Genome siRNA Libraries were screened using FaDu cells (human hypopharyngeal squamous cell cancer). Radiosensitizing targets were subjected to in vitro and in vivo characterizations.
Sixty-seven target sequences with potential radiosensitizing effects were identified. Targets reducing the surviving fraction by >50% at 2 Gy relative to their un-irradiated counterparts were selected for further evaluation. A key regulator of heme biosynthesis, uroporphyrinogen decarboxylase (UROD), was thereby identified as a novel tumor-selective radiosensitizing target, demonstrating both in vitro and in vivo efficacy. Radiosensitization appeared to be mediated via enhancement of tumor oxidative stress from perturbation of iron homeostasis and increased free radical production. UROD was significantly over-expressed in HNC patient biopsies, wherein lower pre-radiation mRNA levels correlated with improved survival, suggesting UROD could potentially predict radiation response. UROD down-regulation also radiosensitized several different human cancer models, while sparing normal cells.
An RNAi-based radiosensitizer HTS has revealed UROD as a potent tumor-selective sensitizer for radiation, with potential relevance to many human malignancies.
Canadian Institutes of Health Research (CIHR; grant 69023); Elia Chair in Head and Neck Cancer Research; philanthropic support from Wharton Family, J. Finley, and G. Tozer; Campbell Family Institute for Cancer Research; Ministry of Health and Long-Term Planning; CIHR Resource Maintenance grant (PRG-82679).
About this article
Cite this article
Ito, E., Yue, S., Moriyama, E.H. et al. Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment. BMC Proc 7, P19 (2013) doi:10.1186/1753-6561-7-S2-P19
- Surrounding Normal Tissue
- Heme Biosynthesis
- Radiosensitizing Effect
- Enhance Tumor Cell
- FaDu Cell